Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Allergy | Botox | Health | Marketing | Study